

(19) World Intellectual Property  
Organization  
International Bureau



10/517869  
Rec'd PCT/PTO 16 DEC 2004



(43) International Publication Date  
31 December 2003 (31.12.2003)

PCT

(10) International Publication Number  
**WO 2004/000316 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 31/44**, 31/4439, A61P 1/04
- (21) International Application Number: **PCT/US2003/016223**
- (22) International Filing Date: **19 June 2003 (19.06.2003)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**0201943-8** **20 June 2002 (20.06.2002)** **SE**
- (71) Applicants (*for all designated States except US*): **AS-TRAZENECA AB [SE/SE]**; R & D Headquarters, Global Intellectual Property, S-151 85 Sodertalje (SE). **NPS PHARMACEUTICALS, INC. [US/US]**; 420 Chipeta Way, Suite 240, Salt Lake City, UT 84108 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **LEHMANN, Anders [SE/SE]**; Borghamnsg. 14, S-421 66 Västra Frölunda (SE). **MATTSSON, Jan [SE/SE]**; Kullaviksvägen 137, S-429333 Kullavik (SE).
- (74) Agents: **BENT, Stephen, A. et al.**; Foley & Lardner, Washington Harbour, Suite 500, 3000 K Street, N.W., Washington, DC 20007-5101 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **USE OF MGLUR5 ANTAGONISTS FOR THE TREATMENT OF GERD**

(57) **Abstract:** The present invention relates to the use of metabotropic glutamate receptor 5 antagonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspects of the invention is directed to the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastro, esophageal reflux disease, as well as for the treatment of regurgitation and asthma.

WO 2004/000316 A1